References
- Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. As nosocomial pathogens: microbiological, clinical and epidemio-logical features. Clin Microbiol Rev 1996; 344: 1329–32.
- Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerg-ing antibiotic for multidrug-resistant Gram-negative bacterial in-fections. Lancet Infect Dis. 2006; 6 (9): 589–601.
- Pankey GA. Tigecycline. J Antimicrob Chemother. 2005; 56 (3): 470–80.
- Curcio D, Fernandez F, Duret F. Initial use of tigecycline in Argentina. Rev Chilena Infectol. 2007; 24 (6): 497–9.
- Clinical and Laboratory Standards Institute. 2007. M100—S17: performance standards for antimicrobial susceptibility test-ing, 17th informational supplement. CLSI, Wayne, PA.
- Lemeshow S, Teres D, Klar J, et al. Mortality probability models (MPM II) based on an international cohort of intensive care patients. JAMA 1993; 270: 2478–86.
- Bantar C, Famiglietti A, Goldberg M. Three-year surveil-lance study of nosocomial bacterial resistance in Argentina. The Antimicrobial Committee; and the National Surveillance Program (SIR) Participants Group. Int J Infect Dis. 2000; 4 (2): 85–90.
- Pasterán F, Rapoport M, Petroni A et al. Emergence of PER-2 and VEB-la in Acinetobacter baumannii strains in the Americas. Antimicrob Agents Chemother 2006; 50: 3222–4.
- Song JY, Kee SY, Hwang IS, et al. In vitro activities of car-bapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acine-tobacter baumannii. J Antimicrob Chemother. 2007; 60 (2): 317–22.
- Ratnam I, Franklin C, Spelman DW. In vitro activities of ‘new’ and ‘conventional’ antibiotics against multi-drug resistant Gram negative bacteria from patients in the intensive care unit. Pathology 2007; 39: 586–8.
- Conte JE, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents. 2005; 25 (6): 523–9.
- Schafer JJ, Goff DA, Stevenson KB, et al. Early experi-ence with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter bau-mannii. Pharmacotherapy. 2007; 27 (7): 980–7.
- Rue M, Artigas A, Alvarez M, et al. Performance of the Mortality Probability Models in assesing severity of iones during the first week in the intensive care unit. Crit Care Med 2000; 28 (8): 2819–24.
- Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buis-son C. The attributable morbidity and mortality of ventilator-as-sociated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med. 1999; 159 (4 Pt 1): 1249-56.